Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics

被引:160
作者
Folpe, AL
Chand, EM
Goldblum, JR
Weiss, SW
机构
[1] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA
[2] Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA
关键词
Fli-1; protein; immunohistochemistry; angiosarcoma; hemangioendothelioma; hemangioma; vascular tumors;
D O I
10.1097/00000478-200108000-00011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Fli-1 protein, a member of the ETS family of DNA-binding transcription factors, is involved in cellular proliferation and tumorigenesis. Approximately 90% of Ewing's sarcoma/primitive neuroectodermal tumors (ES/PNET) have a specific translocation, t(11;22)(q24;q12), which results in fusion of EWS to Fli-1, and production of an EWS-Fli-1 fusion protein. We have recently shown that immunohistochemistry for the carboxy terminal of Fli-1 protein is sensitive and highly specific for the diagnosis of ES/PNET. In our earlier study we noted that among, normal tissues only endothelial cells and small lymphocytes expressed Fli-1. Fli-1 expression in vascular neoplasms has not been previously studied. Formalin-fixed paraffin-embedded tissue from 54 vascular tumors and 75 nonvascular tumors were immunostained for Fli-1 (1: 120, Sc 356, Santa Cruz Biotechnology, Santa Cruz, CA), after steam heat-induced epitope retrieval. Only cases with >10% of cells showing nuclear staining were accepted as positive. Cases without positive internal controls (endothelium and small lymphocytes) were not scored. Positive internal controls were present in 122 of 129 cases (95%). One vascular tumor (Kaposi's sarcoma) and 7 nonvascular tumors (2 epithelioid sarcomas and 5 carcinomas) without internal controls were not scored, Fli-1 was expressed by 50 of 53 vascular tumors scored (94%), including 20 of 22 angiosarcomas, 11 of 12 hemangioendotheliomas, 7 of 7 hemangiomas, and 12 of 12 Kaposi's sarcomas. In contrast, Fli-1 expression was absent in the 68 nonvascular tumors scored (0 of 68), including 16 sarcomas, 7 melanomas, and 45 carcinomas. The results of this study strongly suggest a role for Fli-1 as a novel marker of both benign and malignant vascular tumors. The sensitivity (94%) and specificity (100%) of Fli-1 with regards to the cases evaluated in this study equal or exceed those of the established vascular markers, CD31, CD34, and von Willebrand factor. As the first nuclear, rather than cytoplasmic or membranous marker of endothelium, Fli-1 immunostaining also generally lacks cytoplasmic staining artifacts that are the result of endogenous peroxidases or biotin.
引用
收藏
页码:1061 / 1066
页数:6
相关论文
共 39 条
[1]  
Anderson MK, 1999, DEVELOPMENT, V126, P3131
[2]  
[Anonymous], 1995, SOFT TISSUE TUMORS
[3]  
BENIZHAK O, 1992, CANCER, V69, P1808, DOI 10.1002/1097-0142(19920401)69:7<1808::AID-CNCR2820690724>3.0.CO
[4]  
2-E
[5]   Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries -: Podoplanin as a specific marker for lymphatic endothelium [J].
Breiteneder-Geleff, S ;
Soleiman, A ;
Kowalski, H ;
Horvat, R ;
Amann, G ;
Kriehuber, E ;
Diem, K ;
Weninger, W ;
Tschachler, E ;
Alitalo, K ;
Kerjaschki, D .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (02) :385-394
[6]   Insights into early vasculogenesis revealed by expression of the ETS-domain transcription factor Fli-1 in wild-type and mutant zebrafish embryos [J].
Brown, LA ;
Rodaway, ARF ;
Schilling, TF ;
Jowett, T ;
Ingham, PW ;
Patient, RK ;
Sharrocks, AD .
MECHANISMS OF DEVELOPMENT, 2000, 90 (02) :237-252
[7]   Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family [J].
de Alava, E ;
Gerald, WL .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :204-213
[8]   CD31 immunoreactivity in carcinomas and mesotheliomas [J].
De Young, BR ;
Frierson, HF ;
Ly, MN ;
Smith, D ;
Swanson, PE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 110 (03) :374-377
[9]   Immunohistochemical detection of FLI-1 protein expression - A study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor [J].
Folpe, AL ;
Hill, CE ;
Parham, DM ;
O'Shea, PA ;
Weiss, SW .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (12) :1657-1662
[10]   Vascular endothelial growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas [J].
Folpe, AL ;
Veikkola, T ;
Valtola, R ;
Weiss, SW .
MODERN PATHOLOGY, 2000, 13 (02) :180-185